Callan Family Office LLC Buys New Stake in Insulet Corporation $PODD

Key Points

• Callan Family Office LLC has acquired a new stake in Insulet Corporation, purchasing 1,193 shares valued at approximately $375,000 during the second quarter.
• Insulet's stock has recently experienced a 1.8% decline, and the company reported significant earnings, with $1.17 earnings per share for the last quarter, beating expectations.
• Wall Street analysts have generally positive views on Insulet, with 18 analysts rating it as a Buy, and recent target price adjustments ranging between $300.00 and $370.00.

Callan Family Office LLC purchased a new stake in Insulet Corporation (NASDAQ:PODD - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 1,193 shares of the medical instruments supplier's stock, valued at approximately $375,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. Inspire Investing LLC lifted its position in shares of Insulet by 299.5% during the first quarter. Inspire Investing LLC now owns 4,119 shares of the medical instruments supplier's stock worth $1,082,000 after purchasing an additional 3,088 shares in the last quarter. Gradient Investments LLC acquired a new position in shares of Insulet during the second quarter worth approximately $17,429,000. Goldman Sachs Group Inc. lifted its position in shares of Insulet by 1.9% during the first quarter. Goldman Sachs Group Inc. now owns 579,302 shares of the medical instruments supplier's stock worth $152,130,000 after purchasing an additional 10,628 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Insulet by 55.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock worth $1,376,000 after purchasing an additional 1,867 shares in the last quarter. Finally, Vident Advisory LLC acquired a new position in shares of Insulet during the first quarter worth approximately $216,000.

Insulet Stock Down 1.8%

Insulet stock opened at $312.45 on Thursday. The company has a market cap of $21.99 billion, a P/E ratio of 94.97, a price-to-earnings-growth ratio of 2.66 and a beta of 1.40. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50. The company has a fifty day simple moving average of $325.73 and a 200 day simple moving average of $301.23. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm's revenue for the quarter was up 32.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research reports. Wells Fargo & Company upped their target price on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Rothschild & Co Redburn increased their price objective on shares of Insulet from $350.00 to $370.00 and gave the company a "buy" rating in a report on Friday, October 3rd. The Goldman Sachs Group cut their price objective on shares of Insulet from $399.00 to $375.00 and set a "buy" rating on the stock in a report on Wednesday, October 1st. Royal Bank Of Canada increased their price objective on shares of Insulet from $350.00 to $365.00 and gave the company an "outperform" rating in a report on Friday, October 10th. Finally, Barclays increased their price objective on shares of Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a report on Thursday, August 21st. Eighteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $348.05.

Insiders Place Their Bets

In other news, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Prem Singh sold 687 shares of the firm's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.